Holder Nantahala Capital Management Has Raised Jamba (JMBA) Position; As Alexion Pharmaceuticals (ALXN) Market Value Declined, Opus Point Partners Management Lowered Holding by $3.30 Million

February 15, 2018 - By Peter Erickson

Opus Point Partners Management Llc decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 67.29% based on its latest 2017Q3 regulatory filing with the SEC. Opus Point Partners Management Llc sold 23,553 shares as the company’s stock declined 11.63% while stock markets rallied. The institutional investor held 11,447 shares of the health care company at the end of 2017Q3, valued at $1.61 million, down from 35,000 at the end of the previous reported quarter. Opus Point Partners Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $27.50 billion market cap company. The stock increased 0.70% or $0.86 during the last trading session, reaching $124.06. About 301,455 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 15, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Wilmot B. Harkey increased its stake in Jamba Inc (JMBA) by 38.11% based on its latest 2017Q3 regulatory filing with the SEC. Nantahala Capital Management Llc bought 359,800 shares as the company’s stock declined 25.54% while stock markets rallied. The hedge fund run by Wilmot B. Harkey held 1.30M shares of the consumer services company at the end of 2017Q3, valued at $11.27 million, up from 944,129 at the end of the previous reported quarter. Nantahala Capital Management Llc who had been investing in Jamba Inc for a number of months, seems to be bullish on the $139.35M market cap company. The stock increased 0.33% or $0.03 during the last trading session, reaching $9.09. About 5,125 shares traded. Jamba, Inc. (NASDAQ:JMBA) has declined 34.83% since February 15, 2017 and is downtrending. It has underperformed by 51.53% the S&P500.

Investors sentiment increased to 0.63 in 2017 Q3. Its up 0.06, from 0.57 in 2017Q2. It increased, as 10 investors sold JMBA shares while 14 reduced holdings. 3 funds opened positions while 12 raised stakes. 12.61 million shares or 4.19% less from 13.16 million shares in 2017Q2 were reported. Northern Trust owns 30,843 shares for 0% of their portfolio. Bridgeway Cap Mgmt invested in 0.01% or 89,442 shares. Natl Bank Of America Corp De stated it has 0% in Jamba, Inc. (NASDAQ:JMBA). Element Capital Mgmt Limited Liability Corp holds 0.07% or 19,295 shares. Boothbay Fund Management Limited Liability Company reported 0.04% in Jamba, Inc. (NASDAQ:JMBA). Blackrock reported 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA). Geode Capital Management Ltd holds 0% or 91,082 shares in its portfolio. California Employees Retirement Sys invested 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA). 178,595 are owned by Numeric Invsts. Capital Prns Limited Liability Co invested in 1.43M shares or 1.25% of the stock. Tower Research Capital Limited Liability (Trc) owns 2,035 shares. Barclays Public Ltd Liability Corp stated it has 0% in Jamba, Inc. (NASDAQ:JMBA). Dimensional Fund Ltd Partnership, Texas-based fund reported 309,027 shares. Comml Bank Of New York Mellon has invested 0% of its portfolio in Jamba, Inc. (NASDAQ:JMBA). Deutsche National Bank Ag stated it has 32 shares or 0% of all its holdings.

Nantahala Capital Management Llc, which manages about $614.40 million and $2.04 billion US Long portfolio, decreased its stake in Bridgepoint Ed Inc (Call) (NYSE:BPI) by 843,589 shares to 550,000 shares, valued at $5.28M in 2017Q3, according to the filing. It also reduced its holding in Evolution Petroleum Corp (NYSEMKT:EPM) by 432,556 shares in the quarter, leaving it with 130,615 shares, and cut its stake in Scientific Games Corp (NASDAQ:SGMS).

Among 3 analysts covering Jamba (NASDAQ:JMBA), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Jamba had 5 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of Jamba, Inc. (NASDAQ:JMBA) earned “Neutral” rating by Wedbush on Tuesday, November 22. The stock has “Sell” rating by TheStreet on Wednesday, August 26. The stock of Jamba, Inc. (NASDAQ:JMBA) earned “Neutral” rating by Dougherty & Company on Tuesday, November 10.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.20, from 1.37 in 2017Q2. It is negative, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Hartford Invest Management accumulated 48,075 shares. Livforsakringsbolaget Skandia Omsesidigt holds 0.05% or 4,272 shares. Kentucky Retirement Sys Trust Fund reported 0.15% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Jpmorgan Chase & has invested 0.05% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). State Bank Of The West accumulated 48,618 shares or 0.86% of the stock. Invesco Ltd, a Georgia-based fund reported 4.72 million shares. Farmers Merchants Investments holds 75 shares. Employees Retirement Association Of Colorado owns 41,167 shares for 0.04% of their portfolio. American Century Companies reported 920,074 shares or 0.13% of all its holdings. Winslow Evans & Crocker invested in 404 shares. 73,400 are held by Adams Diversified Equity Fund. Moreover, Bb Biotech Ag has 5.26% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1.35 million shares. Sg Americas Secs Limited Company holds 96,444 shares or 0.12% of its portfolio. Gardner Lewis Asset LP reported 9,425 shares. Texas Permanent School Fund reported 0.11% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Opus Point Partners Management Llc, which manages about $111.46 million US Long portfolio, upped its stake in Bristol Myers Squibb Co (NYSE:BMY) by 45,000 shares to 90,000 shares, valued at $5.74 million in 2017Q3, according to the filing.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Thursday, July 27. Vetr upgraded the stock to “Buy” rating in Wednesday, August 12 report. The rating was initiated by Raymond James with “Strong Buy” on Tuesday, September 1. Robert W. Baird maintained it with “Hold” rating and $145.0 target in Tuesday, October 24 report. The firm has “Equal-Weight” rating given on Friday, July 29 by Barclays Capital. Leerink Swann maintained it with “Outperform” rating and $211 target in Monday, September 26 report. Morgan Stanley maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Tuesday, June 7. Morgan Stanley has “Overweight” rating and $189 target. As per Tuesday, October 24, the company rating was maintained by Leerink Swann. The company was maintained on Friday, February 17 by RBC Capital Markets. BMO Capital Markets maintained the shares of ALXN in report on Friday, July 28 with “Outperform” rating.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>